Dimensional Fund Advisors’s Satsuma Pharmaceuticals STSA Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2023
Q1
– Sell
-231,417
Closed -$209K – 3522
2022
Q4
$209K Sell
231,417
-44,849
-16% -$130K ﹤0.01% 3219
2022
Q3
$1.66M Buy
276,266
+39,731
+17% +$225K ﹤0.01% 2765
2022
Q2
$979K Buy
236,535
+16,671
+8% +$58.8K ﹤0.01% 2917
2022
Q1
$835K Buy
219,864
+17,180
+8% +$77.4K ﹤0.01% 3032
2021
Q4
$912K Sell
202,684
-30,079
-13% -$153K ﹤0.01% 3048
2021
Q3
$1.08M Buy
232,763
+54,765
+31% +$290K ﹤0.01% 3034
2021
Q2
$1.26M Buy
177,998
+125,745
+241% +$678K ﹤0.01% 2984
2021
Q1
$309K Buy
+52,253
New +$317K ﹤0.01% 3220

Other funds holding STSA

Dimensional Fund Advisors's STSA Position: Q1 2023 in Review

Dimensional Fund Advisors sold out of Satsuma Pharmaceuticals (STSA) in Q1 2023, closing a stake of 231,417 shares — an estimated $209K sold.

Dimensional Fund Advisors first reported a position in STSA in Q1 2021 and held it in 8 quarters. The position peaked at $1.66M in Q3 2022. 31 funds tracked by Wall St. Rank hold STSA as of Q1 2023.

  • Dimensional Fund Advisors reported no remaining Satsuma Pharmaceuticals position as of Q1 2023 after selling out during the quarter.
  • Dimensional Fund Advisors sold 231,417 Satsuma Pharmaceuticals shares in Q1 2023, an estimated $209K.
  • Dimensional Fund Advisors first reported a position in Satsuma Pharmaceuticals in Q1 2021 and held it in 8 quarters.
  • Dimensional Fund Advisors's Satsuma Pharmaceuticals position peaked at $1.66M in Q3 2022.
  • 31 funds tracked by Wall St. Rank held Satsuma Pharmaceuticals as of Q1 2023.

Based on Dimensional Fund Advisors's 13F filing for Q1 2023, filed 12 May 2023.